D-0480-2023 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0480-2023 was initiated by Direct Rx on Mar 13, 2023 and is designated Class II. Reason for recall: cGMP deviations The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 30 count: 4 bottles; 90 count: 172 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 5, 2023
Initiation Date
Mar 13, 2023
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
30 count: 4 bottles; 90 count: 172 bottles

Product description

Glimepiride, USP, 1 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0723-30; b) 90-count bottle, NDC 61919-0723-90 Packaged and Distributed By: Direct Rx, Dawsonville, GA 30534

Reason for recall

cGMP deviations

Distribution pattern

Nationwide in the USA

Code information

a) [30 count bottles] Lot, expiry: 07MA2208, exp 5/31/2024 b) [90 count bottles] Lot, expiry: 09AU2128 , exp 1/31/2024; 28JY2102 , exp 1/31/2024; 06AU2103 , exp 1/31/2024 ; 03JA2210 , exp 1/31/2024 ; 14JY2114 , exp 1/31/2024 ; 05NO2106 , exp 2/29/2024 ; 13OC2118 , exp 2/29/2024 ; 08DE2121 , exp 2/29/2024 ;

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0480-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0480-2023. Report a data issue: hello@regdatalab.com.